Lyell Immunopharma, Inc. (LYEL) Financials
LYEL Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 750.0 million | 95.1 million |
2023-09-30 | 795.0 million | 97.4 million |
2023-06-30 | 835.4 million | 98.5 million |
2023-03-31 | 880.5 million | 96.6 million |
LYEL Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -40.7 million | 8.5 million |
2023-09-30 | -37.9 million | 10.5 million |
2023-06-30 | -40.1 million | 14.2 million |
2023-03-31 | -47.7 million | 13.9 million |
LYEL Net Income
No data available :(
LYEL Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 546.2 million | - | 63.2 million |
2023-09-30 | 575.4 million | - | 58.6 million |
2023-06-30 | 595.7 million | - | 60.2 million |
2023-03-31 | 612.8 million | - | 61.8 million |
LYEL Shares Outstanding
LYEL Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 25000 | 41.6 million | 13.2 million | - |
2023-09-30 | 195000 | 43.8 million | 15.5 million | - |
2023-06-30 | 933000 | 47.5 million | 19.0 million | - |
2023-03-31 | 1.5 million | 44.6 million | 19.3 million | - |
LYEL Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 13000 | 5.1 million |
2023-09-30 | 25000 | 5.1 million |
2023-06-30 | 27000 | 4.5 million |
2023-03-31 | 65000 | 5.0 million |
LYEL
Price: $2.38
52 week price:
Earnings Per Share: -0.92 USD
P/E Ratio: -2.25
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 208634
Market Capitalization: 531.1 million